Evidence map›Paper›PMID 35470467›Full record

ArticleFundamental & clinical pharmacology2022

Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice.

Lili Xu, Yaran Gao, Ming Hu, Yanhong Dong, Jing Xu, Jiawei Zhang, Peiyuan Lv

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental & clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Drug Design for Cerebral Ischemia: A Molecular Perspective Review.CNS & neurological disorders drug targets · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lili XuHebei North University, Zhangjiakou, China.ORCID https://orcid.org/0000-0002-0449-535X
Yaran GaoDepartment of Neurology, Hebei Medical University, Shijiazhuang, China.
Ming HuDepartment of Neurology, Hebei General Hospital, Shijiazhuang, China.
Yanhong DongDepartment of Neurology, Hebei General Hospital, Shijiazhuang, China.
Jing XuDepartment of Neurology, Hebei General Hospital, Shijiazhuang, China.
Jiawei ZhangDepartment of Neurology, Hebei Medical University, Shijiazhuang, China.
Peiyuan LvHebei North University, Zhangjiakou, China.
Hebei General Hospital · CNHebei Medical University · CNHebei North University · CN

Funding

2019 Hebei Provincial Government funded clinical Talents Training Project 2019-139-5Hebei Provincial High-end Talents Funding Project 6833452Hebei Provincial High-end Talents Funding Project 83587216Project of Introducing Talents to Hebei Province 2020-19-2
6 · The paper itself

Abstract

Stroke is the leading cause of disability and death. When blood flow is restored after prolonged ischemia and hypoxia, it leads to excessive production of reactive oxygen species (ROS), increased local inflammation, and apoptosis, which are the cause of most cerebral ischemia reperfusion injury (CIRI), leading to secondary brain tissue damage. Edaravone dexborneol is a novel neuroprotective agent consisting of edaravone and borneol. Studies have shown that it has synergistic antioxidant and anti-inflammatory effects. However, whether Edaravone dexborneol stimulates the Nrf2/HO-1 pathway to regulate NADPH oxidase 2 (NOX2) remains unclear. In this study, wild-type (WT) mice and Nrf2 knockout (KO) mice were used to investigate the antioxidant, anti-inflammatory, and anti-apoptotic effects of Edaravone dexborneol on CIRI and its mechanism. The cognitive function of mice was evaluated with the Morris water maze (MWM), test and the cell structures of hippocampus were observed by hematoxylin and eosin (H&E) staining. Nrf2, HO-1, and NOX2 proteins and apoptosis-related proteins Bcl-2, Bax, and Caspase 3 were detected by western blotting. Nrf2, HO-1, NOX2, and inflammatory factors TNF-α, IL-1β, IL-4, and IL-10 were detected by real-time polymerase chain reaction. The results showed that Edaravone dexborneol treatment improved learning and memory performance, neuronal damage, and enhanced antioxidant, inflammation, and apoptosis in CIRI mice. In addition, Edaravone dexborneol induced the activation Nrf2/HO-1 signaling pathway activation while inhibiting NOX2 expression. Overall, these results indicate that Edaravone dexborneol ameliorates CIRI-induced memory impairments by activating Nrf2/HO-1 signaling pathway and inhibiting NOX2.

Indexed as

Brain IschemiaReperfusion InjuryAnimalsAntioxidantsApoptosisEdaravoneHeme Oxygenase-1InflammationMembrane ProteinsMiceNF-E2-Related Factor 2Oxidative StressRatsRats, Sprague-DawleySignal TransductionAntioxidantsEdaravoneHeme Oxygenase-1Hmox1 protein, mouseMembrane ProteinsNF-E2-Related Factor 2cerebral ischemia reperfusion injuryEdaravone dexborneolinflammationNADPH oxidase 2Nrf2/HO-1 pathway

Identifiers

PMID35470467
PMCPMC9545784
OpenAlexW4224861697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.